Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease

Biomarkers

Volumn 14, Issue 7, 2009, Pages 493-501

  Roher, Alex E ^a   Maarouf, Chera L ^a   Sue, Lucia I ^b   Hu, Yiran ^c   Wilson, Jeffrey ^c   Beach, Thomas G ^b  

^a Longtine Center for Molecular Biology and Genetics   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

1 acid glycoprotein; A ; Alzheimers disease; Apolipoprotein A 1; Biomarkers; Cerebrospinal fluid; ELISA; Haemopexin; Haptoglobin; Non Alzheimer s disease dementias; Pigment epithelium derived factor; Tau; Transthyretin; Zinc a 2 glycoprotein

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BIOLOGICAL MARKER; HAPTOGLOBIN; HEMOPEXIN; OROSOMUCOID; PIGMENT EPITHELIUM DERIVED FACTOR; PREALBUMIN; TAU PROTEIN; UNCLASSIFIED DRUG; ZINC ALPHA 1 ACID GLYCOPROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN VENTRICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NEUROPATHOLOGY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN A-I; AUTOPSY; BIOLOGICAL MARKERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOPEXIN; HUMANS; LOGISTIC MODELS; MALE; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 70449348828     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903108423     Document Type: Article

References (69)

1. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, Lindau M, Eriksdotter-Jonhagen M. (2008). Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 29:1466-1473
2. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J. (2008). The Sun Health Research Institute Brain Donation Program: Description and Experience, 1987- 2007. Cell Tissue Bank 9:229-245
3. Bouwman FH, van Der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, Blankenstein MA, Scheltens P. (2007). Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69:1006-1011
4. Burgess JA, Lescuyer P, Hainard A, Burkhard PR, Turck N, Michel P, Rossier JS, Reymond F, Hochstrasser DF, Sanchez JC. (2006). Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid. J Proteome Res 5:1674-1681
5. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. (2006). Comparative proteomics of cerebrospinal fluid in neuropathologically confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 28:155-163
6. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Jr., Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ. (2003). Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60:1696-1702
7. Davidsson P, Folkesson S, Christiansson M, Lindbjer M, Dellheden B, Blennow K, Westman-Brinkmalm A. (2002). Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom 16:2083-2088
8. Davidsson P, Westman A, Puchades M, Nilsson CL, Blennow K. (1999). Characterization of proteins from human cerebrospinal fluid by a combination of preparative two-dimensional liquid-phase electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem 71:642-647
9. Dayon L, Hainard A, Licker V, Turck N, Kuhn K, Hochstrasser DF, Burkhard PR, Sanchez JC. (2008). Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 80:2921-2931
10. Dickson DW. (2005). Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol 109:14-24.
11. Dittmer S, Sahin M, Pantlen A, Saxena A, Toutzaris D, Pina AL, Geerts A, Golz S, Methner A. (2008). The constitutively active orphan G-protein-coupled receptor GPR39 protects from cell death by increasing secretion of pigment epithelium-derived growth factor. J Biol Chem 283:7074-7081
12. Elovaara I, Icen A, Palo J, Erkinjuntti T. (1985). CSF in Alzheimer's disease. Studies on blood-brain barrier function and intrathecal protein synthesis. J Neurol Sci 70:73-80.
13. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP. (2008). Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29:1143-1159
14. Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, Watson M, Fryer JD, Wahrle S, Bales KR, Paul SM, Holtzman DM. (2004). ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol 165:1413-1422
15. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. (2007). Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343-349
16. Fasano M, Mattu M, Coletta M, Ascenzi P. (2002). The heme-iron geometry of ferrous nitrosylated heme-serum lipoproteins, hemopexin, and albumin: a comparative EPR study. J Inorg Biochem 91:487-490
17. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S, Budka H, Carmona M, Giaccone G, Krebs B, Limido L, Parchi P, Puig B, Strammiello R, Strobel T, Kretzschmar H. (2007). Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologicdiseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol 66:35-46.
18. Finehout EJ, Franck Z, Relkin N, Lee KH. (2006). Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. Clin Chem 52:1906-1913
19. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. (1998). High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55:937-945
20. Gartner U, Janke C, Holzer M, Vanmechelen E, Arendt T. (1998). Postmortem changes in the phosphorylation state of tau-protein in the rat brain. Neurobiol Aging 19:535-543
21. Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I. (2008). Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 14:17-25.
22. Hansson SF, Puchades M, Blennow K, Sjogren M, Davidsson P. (2004). Validation of a prefractionation method followed by two-dimensional electrophoresis - applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci 2:7.
23. Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ. (1996). Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem 66:2429-2435
24. Jellinger KA. (1996). Structural basis of dementia in neurodegenerative disorders. J Neural Transm Suppl 47:1-29.
25. Jellinger KA. (2002). Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109:813-836
26. Johnson G, Brane D, Block W, van Kammen DP, Gurklis J, Peters JL, Wyatt RJ, Kirch DG, Ghanbari HA, Merril CR. (1992). Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. Appl Theor Electrophor 3:47-53.
27. Jung SM, Lee K, Lee JW, Namkoong H, Kim HK, Kim S, Na HR, Ha SA, Kim JR, Ko J, Kim JW. (2008). Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Neurosci Lett 436:153-157
28. Kawashiri MA, Zhang Y, Pure E, Rader DJ. (2002). Combined effects of cholesterol reduction and apolipoprotein A-I expression on atherosclerosis in LDL receptor deficient mice. Atherosclerosis 165:15-22.
29. Kazee AM, Eskin TA, Lapham LW, Gabriel KR, McDaniel KD, Hamill RW. (1993). Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord 7:152-164
30. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS. (2001). Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 40:3553-3560
31. Kosunen O, Soininen H, Paljarvi L, Heinonen O, Talasniemi S, Riekkinen PJ Sr. (1996). Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol 91:185-193 Lescuyer P, Allard L, Zimmermann-Ivol CG, Burgess JA, Hughes-
32. Frutiger S, Burkhard PR, Sanchez JC, Hochstrasser DF. (2004). Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics 4:2234-2241
33. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ. (2007). CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69:631-639
34. Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB. (1999). Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 47:564-569
35. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW. (1996). Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55:97-105.
36. Liu HC, Hu CJ, Chang JG, Sung SM, Lee LS, Yuan RY, Leu SJ. (2006). Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 21:155-161
37. Luoma PV. (1997). Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity. Pharmacol Toxicol 81:57-64.
38. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C. (2003). Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 60:1202-1206
39. Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, Montine TJ, Montine KS. (2004). Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem 91:1312-1321
40. Mattila KM, Pirttila T, Blennow K, Wallin A, Viitanen M, Frey H. (1994). Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand 89:192-198
41. Mauk MR, Rosell FI, Lelj-Garolla B, Moore GR, Mauk AG. (2005). Metal ion binding to human hemopexin. Biochemistry 44:1864-1871
42. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH. (1998). Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 338:506-511 (Pubitemid 28103134)
43. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. (1991). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479-486
44. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF. (2001). Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 125:510-512
45. Morello N, Tonoli E, Logrand F, Fiorito V, Fagoonee S, Turco E, Silengo L, Vercelli A, Altruda F, Tolosano E. (2008). Hemopexin affects iron distribution and ferritin expression in mouse brain. J Cell Mol Med Dec 16 [Epub ahead of print].
46. Nagga K, Gottfries J, Blennow K, Marcusson J. (2002). Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 14:183-190, National Institute on Aging, and Reagan Institute. (1997). Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18:S1-S2.
47. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM. (2004). Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol 15:645-649
48. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. (2003). Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292-2300
49. Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P. (2006). Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mech Ageing Dev 127:129-132
50. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. (2003). Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 118:140-146 (Pubitemid 37238996)
51. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. (2007). Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13:1359-1362
52. Reiber H. (2001). Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173-186
53. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. (2002). Cerebrospinal fluid tau and betaamyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59:1729-1734
54. Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ. (2006). Effect of a short-term diet and exercise intervention on inflammatory/ anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 101:1727-1732
55. Saczynski JS, White L, Peila RL, Rodriguez BL, Launer LJ. (2007). The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am J Epidemiol 165:985-992 (Pubitemid 46598838)
56. Sakata N, Hoshii Y, Nakamura T, Kiyama M, Arai H, Omoto M, Morimatsu M, Ishihara T. (2005). Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. J Histochem Cytochem 53:237-242
57. Schwab C, Bondada V, Sparks DL, Cahan LD, Geddes JW. (1994). Postmortem changes in the levels and localization of microtubule- associated proteins (tau, MAP2 and MAP1B) in the rat and human hippocampus. Hippocampus 4:210-225
58. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K. (2001). Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70:624-630
59. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. (2003). Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 15:169-176
60. Soffer D. 2006. Cerebral amyloid angiopathy - a disease or age-related condition. Isr Med Assoc J 8:803-806
61. Sreekumar PG, Zhou J, Sohn J, Spee C, Ryan SJ, Maurer BJ, Kannan R, Hinton DR. (2008). N-(4-hydroxyphenyl) retinamide augments laser-induced choroidal neovascularization in mice. Invest Ophthalmol Vis Sci 49:1210-1220
62. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L. (2008). Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65:256-263
63. Tapiola T, Pirttila T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H. (2000). Relationship between apoE genotype and CSF betaamyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 21:735-740
64. Tolosano E, Hirsch E, Patrucco E, Camaschella C, Navone R, Silengo L, Altruda F. (1999). Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice. Blood 94:3906-3914
65. Vanderstichele H, De VK, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Burger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Blaser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E. (2006). Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 44:1472-1480
66. Victoroff J, Mack WJ, Lyness SA, Chui HC. (1995). Multicenter clinicopathological correlation in dementia. Am J Psychiatry 152:1476-1484
67. Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B. (1995). Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol 147:238-244
68. Yu HL, Chertkow HM, Bergman H, Schipper HM. (2003). Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3:2240-2248
69. Zheng PP, Luider TM, Pieters R, Avezaat CJ, van den Bent MJ, Sillevis Smitt PA, Kros JM. (2003). Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 62:855-862